Commercial antithrombin concentrate contains inactive L-forms of antithrombin

Thrombosis and Haemostasis

Volumn 77, Issue 2, 1997, Pages 323-328

  Chang, Wun Shaing W ^a,c   Harper, Paul L ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b WEST SUFFOLK HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; ANTITHROMBIN CONCENTRATE; HEPARIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CHROMATOGRAPHY; CONTROLLED STUDY; DRUG CONFORMATION; DRUG INACTIVATION; DRUG SYNTHESIS; HEATING; ISOELECTRIC FOCUSING; ISOELECTRIC POINT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN FOLDING; THERMOSTABILITY;

EID: 0031059479     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1655962     Document Type: Article

References (31)

1. Chang WSW, Bruce D, Lomas DA, Carrell RW, Wardell MR. Antithrombin, pasteurisation and latency: probing the reactive centre loop conformation. Br J Haematol 1994; 86 (suppl. 1): 42.
2. Chang WSW. Conformational mobility and interactions of the serpins. PhD thesis, Cambridge University, UK 1995; pp 92-132.
3. Murano G, Williams L, Miller-Andersson M, Aronson DL, King C. Some properties of antithrombin III and its concentration in human plasma. Thromb Res 1980; 18; 259-62.
4. 1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis. Nature 1985; 317: 730-2.
5. 1-Antitrypsin and the serpins: variation and counter-variation. Trends Biochem Sci 1985; 10: 20-4.
6. Danielsson Å, Björk I. Antithrombin and related inhibitors of coagulation proteinases. In: Proteinase Inhibitors. Barrett AJ, Salvesen G, eds. Elsevier Science Publishers, Amsterdam, NL 1986; pp 489-513.
7. Thaler E, Lechnerk P. Antithrombin III deficiency and thromboembolism. Clin Haematol 1981; 10: 369-90.
8. Winter JH, Fenech A, Ridley W. Familial antithrombin III deficiency. Q J Med 1982; 51: 29-33.
9. Bick RL, Bick MD, Fekete LF. Antithrombin III patterns in disseminated intravascular coagulation. Am J Clin Path 1980; 73: 577-83.
10. Wilson RF, Mammen EF, Robson MC. Antithrombin, prekallikrein, and fibronectin levels in surgical patients. Arch Surg 1986; 121: 635-40.
11. Blauhut B, Necek S, Vinazzer H, Bergman H. Substitution therapy with antithrombin III concentrate in shock and DIC. Thromb Res 1982; 27: 271-8.
12. Schechter I, Berger A. On the size of the active site in proteases. 1. papain. Biochem Biophys Res Commun 1967; 27: 157-62.
13. Stein PE, Leslie AGW, Finch JT, Turnell WG, McLaughlin PJ, Carrell RW. Crystal structure of ovalbumin as a model for the reactive centre of serpins. Nature 1990; 347: 99-102.
14. 1-proteinase inhibitor: crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol 1984; 177: 531-56.
15. Mourey L, Samama J, Delarue M, Petitou M, Choay J, Moras D. Crystal structure of cleaved bovine antithrombin III at 3.2 Å resolution. J Mol Biol 1993; 232: 223-41.
16. Carrell RW, Stein PE, Fermi G, Wardell MR. Biological implications of a 3 Å structure of dimeric antithrombin. Structure 1994; 2: 257-70.
17. Schreuder HA, de Boer B, Dijkema R, Mulders J, Theunissen HJM, Grootenhuis PDJ, Hol WGJ. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nature Struct Biol 1994; 1: 48-54.
18. Smith JK, Winkelman L, Evans DR, Haddon ME, Sims GA. A pasteurised antithrombin III concentrate for clinical use. Vox Sang 1985; 48: 325-32.
19. 1-antitrypsin. J Biol Chem 1995; 270: 5282-8.
20. McKay EJ. A simple two-step procedure for the isolation of antithrombin III from biological fluids. Thromb Res 1981; 21: 375-82.
21. Nordenman B, Nyström C, Björk I. The size and shape of human and bovine antithrombin III. Eur J Biochem 1977; 78: 195-203.
22. Olson ST, Björk I, Shore JD. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol 1993; 222: 525-59.
23. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
24. Goldenberg DP. Analysis of protein conformation by gel electrophoresis. In: Protein Structure, a Practical Approach. Creighton TE, ed. IRL Press, Oxford, UK 1989; pp 225-50.
25. 2-antiplasmin, angiotensinogen and ovalbumin. Biochemistry 1991; 30: 1723-30.
26. 1-antitrypsin. Biochemistry 1993; 32: 500-8.
27. Chang WSW, Wardell MR, Lomas DA, Carrell RW. Probing Serpin reactive loop conformations by proteolytic cleavage. Biochem J 1996; 314: 647-53.
28. Hoffman DL. Purification and large scale preparation of antithrombin III. Am J Med 1989;87:23S-26S.
29. Winkelman L, Haddon ME. Pasteurisation Induced Changes in antithrombin III Concentrate. Thromb Res 1986; 43: 219-27.
30. Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355: 270-3.
31. Lomas DA, Stone SR, Llewellyn-Jones C, Keogan MT, Wang Z, Rubin H, Carrell RW, Stockley RA. The control of neutrophil chemotaxis by inhibitors of Cathepsin G and Chymotrypsin. J Biol Chem 1995; 270: 23437-43.